Uncategorized
This week in Drug Discovery (22-26 June)

News round-up for 22–26 June by Bruno Quinney, Content Team at DDW.
This week, the Summer issue of DDW is now available to read. Elsewhere, researchers have uncovered clues explaining risks of heart disease, lung disease, Covid-19 and cancer.
The top stories:
The DDW Summer 2026 issue examines the multi-compound approach to autism, the outlook for GLP-1 therapies and highlights drug discovery innovators and investors.
Hidden pathway could be targeted to reduce heart disease
A team from the University of California San Diego School of Medicine uncovered a biological pathway involving the liver, explaining why high-cholesterol diets impede the body’s ability to clear harmful low-density lipoprotein (LDL) cholesterol from the blood.
Genetic variation increases Covid-19 and lung disease risk
A genetic difference carried by nearly one in three could increase the risk of Covid-19 and lung disease, a new study shows.
Faster ageing could be linked to developing cancer
Scientists from the PROSPECT team, funded by Cancer Grand Challenges, analysed blood samples and health information from more than 164,000 people from the UK and US, comparing people born across different decades.
Algae microbots increase drug penetration 10x in bladder cancer
Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs into tumours, researchers say.
The post This week in Drug Discovery (22-26 June) appeared first on Drug Discovery World (DDW).